Landogrozumab

Monoclonal antibody

none

IdentifiersCAS Number

1391726-30-9

ChemSpider

none

UNII

B1792M902R

KEGG

D11235

Chemical and physical dataFormulaC₆₃₃₈H₉₇₉₀N₁₆₉₄O₁₉₈₈S₄₂Molar mass142874.43 g·mol⁻¹

Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.^[1]^[2]

This drug was developed by Eli Lilly & Co.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).